What is cyanocobalamin?
Cyanocobalamin is the most common synthetic form of vitamin B12 found in supplements and pharmaceutical preparations. It is stable, inexpensive to manufacture, and well-absorbed when injected. In the body, cyanocobalamin is converted to the active coenzyme forms — methylcobalamin and adenosylcobalamin — which participate in DNA synthesis, red blood cell formation, and neurological function.
B12 deficiency can manifest as fatigue, peripheral neuropathy, megaloblastic anemia, and cognitive changes. In most well-nourished adults eating animal products, deficiency is uncommon. In patients on medications that impair B12 absorption (notably metformin), in people following strict plant-based diets, or in those with GI conditions affecting the terminal ileum where B12 is absorbed, deficiency risk rises.
Why is compounded semaglutide sometimes formulated with B12?
The practical rationale for including B12 in some compounded semaglutide preparations comes from two observations:
1. Appetite suppression may reduce dietary B12 intake
GLP-1 receptor agonists reduce appetite substantially. Patients eating significantly less food over months are, by extension, consuming less B12 from animal-derived foods (meat, fish, dairy, eggs are the primary dietary sources). For patients who were already borderline on B12 intake, the caloric restriction that accompanies GLP-1 therapy can push them into deficit territory.
2. GLP-1 slows gastric emptying, which may affect intrinsic factor
B12 absorption in the terminal ileum requires binding to intrinsic factor, a glycoprotein secreted by gastric parietal cells. GLP-1 receptor agonists slow gastric motility, which theoretically could affect the release and binding dynamics of intrinsic factor — though the clinical evidence here is less well-established than the better-studied B12 depletion mechanism of metformin.
3. Co-formulation as a clinical convenience
From a compounding pharmacy perspective, including B12 in the same injection adds a co-factor with a favorable safety profile and no meaningful interaction with semaglutide. It removes the need for a separate oral supplement or injection for B12 support. Some clinicians prefer to prescribe it separately based on labs; others find the co-formulation a reasonable default.
The B12 in compounded semaglutide is a precautionary, diet-driven addition — not proof that the drug itself depletes B12.
What does the evidence actually show?
It is important to distinguish between established evidence and clinical precaution. Here is the honest state of the literature:
- Metformin and B12 depletion is well-documented. A systematic review and meta-analysis published in Nutrients (2020) confirmed that metformin users have significantly lower serum B12 levels. GLP-1 receptor agonists do not carry the same established depletion mechanism.
- GLP-1 and B12 deficiency is not established in the clinical trial record. The STEP program trials did not identify B12 deficiency as a notable adverse event. The rationale for B12 supplementation in GLP-1 users is primarily precautionary and diet-driven, not a documented pharmacological depletion effect.
- Combined semaglutide/metformin users have a compounded risk from the metformin-B12 mechanism. For this population, monitoring and supplementation has clearer evidence behind it.
- Baseline B12 labs are the right starting point. Whether you need B12 supplementation cannot be answered without knowing your current serum B12 level.
Cyanocobalamin vs. methylcobalamin: which form matters for semaglutide users?
This question comes up frequently. The difference:
- Cyanocobalamin is a synthetic form that must be converted in the body to the active coenzyme forms. It is inexpensive, chemically stable, and effective at raising serum B12 in most people. It is the form used in most pharmaceutical co-formulations.
- Methylcobalamin is the active coenzyme form that does not require conversion. Some practitioners prefer it for patients with genetic variants (MTHFR) that may impair conversion, though the clinical significance of this preference is debated.
For most patients receiving injectable compounded semaglutide with cyanocobalamin, the form difference is clinically minor. If you have a specific reason to prefer methylcobalamin, discuss it with your prescribing clinician.
| Form | Conversion needed? | Stability | Common in compounding? |
|---|---|---|---|
| Cyanocobalamin | Yes — converted to active coenzyme forms in liver | Very stable; preferred in pharma co-formulations | Yes — most pharmaceutical standards |
| Methylcobalamin | No — already the active coenzyme form | Less stable; requires careful storage | Yes — common in 503A injectable formulations |
Is compounded semaglutide the same as Ozempic or Wegovy?
Compounded semaglutide, whether or not it includes B12, is not an FDA-approved drug. It is compounded in the USA by licensed 503A pharmacies, patient-specific, and dispensed pursuant to a clinician prescription. It is not the same as Ozempic or Wegovy. The FDA-approved branded versions of semaglutide do not include B12. Compounded products are not manufactured under the same conditions or testing standards as branded drugs.
PepScribe works exclusively with licensed 503A compounding pharmacies. No hidden overseas supply chain.
What to ask your clinician
- What is my baseline serum B12 level, and do I actually need supplementation?
- Does my prescription include B12, and if so, what dose?
- Am I also taking metformin? (If yes, the B12 monitoring indication is stronger and well-established.)
- Should B12 be checked at follow-up labs, or is the co-formulation considered sufficient?
- Is there a reason to prefer methylcobalamin over cyanocobalamin in my specific case?
Frequently asked questions
Why is B12 added to some compounded semaglutide formulations?
B12 (cyanocobalamin) is added to some compounded semaglutide preparations because GLP-1 receptor agonists slow gastric emptying and can reduce appetite significantly, which may compromise dietary B12 intake over time. Compounding pharmacies include it as a convenience co-formulation. Not all compounded semaglutide includes B12; your prescription specifies the exact formulation.
Does semaglutide deplete vitamin B12?
There is no strong clinical evidence that semaglutide directly depletes B12 in the way that metformin does. However, the appetite suppression and dietary changes that accompany GLP-1 therapy can reduce B12 intake from food. Whether co-formulated B12 meaningfully offsets this depends on the dose and the individual patient's baseline B12 status.
What is the difference between cyanocobalamin and methylcobalamin?
Both are forms of vitamin B12. Cyanocobalamin is the most common form in supplements and co-formulations — it is stable and inexpensive. Methylcobalamin is the active coenzyme form and requires no conversion in the body. In most healthy individuals, both forms are effective at raising serum B12 levels. Your clinician determines which form is appropriate.
Is semaglutide with B12 FDA-approved?
No. Compounded semaglutide — with or without B12 — is not an FDA-approved drug. It is prepared by licensed 503A compounding pharmacies in the United States pursuant to a clinician prescription. It is not the same as Ozempic or Wegovy. The FDA-approved versions of semaglutide do not include B12.
Should I take separate B12 supplements on semaglutide?
Whether you need additional B12 supplementation beyond what may be in your compounded formulation depends on your baseline labs, diet, and any GI conditions that affect B12 absorption. Ask your prescribing clinician to check your B12 level at baseline and monitor it during your protocol.
Can the B12 in a compounded semaglutide injection cause side effects?
B12 injections at therapeutic doses are generally well-tolerated. At very high doses, some individuals report mild injection-site reactions. Serious adverse reactions to B12 injections are rare. If you notice unusual symptoms after injection, contact your clinician.